Who are AVACINCAPTAD PEGOL SODIUM's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Veopoz, Izervay, Ultomiris, Ro 205720, Eculizumab+IVMP, Soliris.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/avacincaptad-pegol-sodium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

AVACINCAPTAD PEGOL SODIUM — Competitive Intelligence Brief

AVACINCAPTAD PEGOL SODIUM (AVACINCAPTAD PEGOL SODIUM) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Complement Inhibitors. Area: Immunology.

marketed Complement Inhibitors Complement C5 Immunology Live · refreshed every 30 min

Target snapshot

AVACINCAPTAD PEGOL SODIUM (AVACINCAPTAD PEGOL SODIUM).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AVACINCAPTAD PEGOL SODIUM TARGET	AVACINCAPTAD PEGOL SODIUM		marketed	Complement Inhibitors	Complement C5	2023-01-01
Veopoz	POZELIMAB	Regeneron	marketed	Complement Inhibitor [EPC]	Complement C5	2023-01-01
Izervay	AVACINCAPTAD PEGOL	Astellas Pharma	marketed		Complement C5	2023-01-01
Ultomiris	RAVULIZUMAB	AstraZeneca	marketed	Complement Inhibitor [EPC]	Complement C5	2018-01-01
Ro 205720	CARPROFEN	Roche	marketed	carprofen	Complement C5, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1987-01-01
Eculizumab+IVMP	Eculizumab+IVMP	Chinese PLA General Hospital	marketed	Complement inhibitor + corticosteroid combination	Complement C5 + glucocorticoid receptor
Soliris	Soliris	Apellis Pharmaceuticals, Inc.	marketed		Complement C5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-11-11 — AVACINCAPTAD PEGOL SODIUM · 8236773 · Method of Use · US
2027-02-14 — AVACINCAPTAD PEGOL SODIUM · 9617546 · Compound · US
2027-02-14 — AVACINCAPTAD PEGOL SODIUM · 7579456 · Compound · US
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · 11491176 · Method of Use · US
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · 11273171 · Method of Use · US
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · 12016875 · Method of Use · US

Sponsor landscape (Complement Inhibitors class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AVACINCAPTAD PEGOL SODIUM — Competitive Intelligence Brief. https://druglandscape.com/ci/avacincaptad-pegol-sodium. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab